We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: NSCLC
MedXY News
EnglishTag

NSCLC

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
Neurologyimmune checkpoint inhibitorsleptomeningeal metastasis

Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes

By MedXY|Nov 12, 2025

An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study
newsEGFR mutationNSCLC
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Efficacy of Afatinib Combined with Chemotherapy in Post-Osimertinib EGFR-Mutated NSCLC: Insights from the NEJ025B Study

By MedXY|Oct 25, 2025

This phase II study evaluates the effectiveness and safety of afatinib with platinum-based chemotherapy in NSCLC patients resistant to first-line osimertinib, highlighting promising outcomes and manageable toxicity.

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib
OncologyeGFRNSCLC

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY|Oct 25, 2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy
newschemotherapyeGFR

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

By MedXY|Oct 25, 2025

This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits
Oncologyclinical trialeGFR

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY|Oct 24, 2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy
Oncologychemotherapyimmunotherapy

Advancing First-Line Treatment in Metastatic NSCLC: The Promise of Retifanlimab Combined with Chemotherapy

By MedXY|Oct 18, 2025

This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.

Reevaluating the Role of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy in Resectable Stage III NSCLC: Results from a Two-Center Real-World Study
Clinical UpdatesNSCLC

Reevaluating the Role of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy in Resectable Stage III NSCLC: Results from a Two-Center Real-World Study

By MedXY|Oct 9, 2025

This study suggests adjuvant immunotherapy may not enhance survival after neoadjuvant chemoimmunotherapy and surgery in stage III NSCLC, with three cycles of neoadjuvant immunotherapy appearing optimal.

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
Clinical UpdatesimmunotherapyNSCLC

Impact of Antibiotics, Steroids, and PPIs on Survival in Advanced NSCLC Patients Treated with First-Line Pembrolizumab

By MedXY|Oct 9, 2025

This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the imp

Clinical UpdatesanlotinibKRAS mutation

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY|Oct 8, 2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC
Clinical UpdatesimmunotherapyNSCLC

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY|Oct 6, 2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role i

High-Dose Vitamin C Induces Pyroptosis in LKB1-Mutant Lung Cancer and Enhances Immunotherapy Response
OncologyimmunotherapyNSCLC

High-Dose Vitamin C Induces Pyroptosis in LKB1-Mutant Lung Cancer and Enhances Immunotherapy Response

By MedXY|Oct 4, 2025

New research reveals that high-dose vitamin C selectively kills LKB1-mutant NSCLC cells by inducing pyroptosis, reversing immunotherapy resistance and improving T cell infiltration through GLUT1-mediated uptake and ROS-mediated cell death.

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial
Clinical UpdatesEGFR mutationNSCLC

Comparative Efficacy and Safety of Limertinib versus Gefitinib in First-Line Treatment of EGFR-Mutated Advanced NSCLC: A Phase 3 Randomized Trial

By MedXY|Oct 1, 2025

Limertinib demonstrates superior progression-free survival and a comparable safety profile to gefitinib, supporting its use as a first-line therapy in EGFR-mutated locally advanced or metastatic NSCLC.

Prev
2 / 2
12
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities